Author: Li, Dongbo; Ji, Hongfei; Niu, Xingjian; Yin, Lei; Wang, Yiran; Gu, Yucui; Wang, Jinlu; Zhou, Xiaoping; Zhang, Han; Zhang, Qingyuan
Title: Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer Document date: 2019_12_19
ID: yj9mb88g_1
Snippet: Breast cancer is the most common cause of cancer-related mortality in women. 1 Approximately 70% of breast cancers are hormone receptor-positive. 2 Although endocrine therapy remains the most effective treatment, its efficacy is limited by intrinsic or acquired endocrine resistance. [3] [4] [5] Tamoxifen, a selective ER modulator, is the most common endocrine therapy worldwide 6 ; hence, resistance to tamoxifen is a major clinical challenge......
Document: Breast cancer is the most common cause of cancer-related mortality in women. 1 Approximately 70% of breast cancers are hormone receptor-positive. 2 Although endocrine therapy remains the most effective treatment, its efficacy is limited by intrinsic or acquired endocrine resistance. [3] [4] [5] Tamoxifen, a selective ER modulator, is the most common endocrine therapy worldwide 6 ; hence, resistance to tamoxifen is a major clinical challenge.
Search related documents:
Co phrase search for related documents- breast cancer and clinical challenge: 1, 2, 3, 4
- breast cancer and common cause: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- breast cancer and common endocrine therapy: 1, 2
- breast cancer and effective treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- breast cancer and endocrine resistance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- breast cancer and endocrine therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69
- breast cancer and major clinical challenge: 1
- breast cancer and receptor positive hormone: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
- breast cancer and tamoxifen resistance: 1, 2, 3, 4, 5, 6, 7
- clinical challenge and common cause: 1, 2, 3, 4, 5, 6, 7
- clinical challenge and effective treatment: 1, 2, 3, 4, 5, 6, 7, 8
- clinical challenge and endocrine resistance: 1
- clinical challenge and endocrine therapy: 1, 2
- clinical challenge and major clinical challenge: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46
- clinical challenge and tamoxifen resistance: 1, 2
- common cause and effective treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
- common cause and effective treatment remain: 1
- common cause and major clinical challenge: 1
- common cause and tamoxifen resistance: 1
Co phrase search for related documents, hyperlinks ordered by date